Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 30, 2009

Optimata and Teva to Repurpose Shelved Cancer Drug Candidates

  • Optimata entered a collaboration with Teva Pharmaceutical to develop candidates for solid tumor cancers. The partners will select compounds that had been previously discontinued in development to re-evaluate.

    Rescue and redirection of the program will be done using Optimata’s predictive biosimulation technology. Optimata Virtual Patient® comprises computer-implemented mathematical algorithms of key physiological, pathological, and pharmacological processes in the body of the patient.

    It then unfolds drug-patient dynamic interactions, enabling drug developers to perform virtual clinical trials and clinical indication match for patient population as well as forecast optimal drug treatments for a given trial end point, according to the companies. Moreover, calibrated with patient-specific parameters, Optimata’s technology can tailor improved treatments of various monotherapies and combination therapies of targeted drugs and chemotherapeutics, they add.

    Optimata will receive up-front payments, development milestones, and royalties. Separately, Teva Pharmaceutical made an undisclosed equity investment in Optimata.

Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »